Sequencing Structural Variants in Cancer for Precision Therapeutics
Trends in Genetics
MetadataShow full item record
Macintyre, G., Ylstra, B., & Brenton, J. (2016). Sequencing Structural Variants in Cancer for Precision Therapeutics. Trends in Genetics, 32 530-542. https://doi.org/10.1016/j.tig.2016.07.002
The identification of mutations that guide therapy selection for patients with cancer is now routine in many clinical centres. The majority of assays used for solid tumour profiling use DNA sequencing to interrogate somatic point mutations because they are relatively easy to identify and interpret. Many cancers, however, including high-grade serous ovarian, oesophageal, and small-cell lung cancer, are driven by somatic structural variants that are not measured by these assays. Therefore, there is currently an unmet need for clinical assays that can cheaply and rapidly profile structural variants in solid tumours. In this review we survey the landscape of ‘actionable’ structural variants in cancer and identify promising detection strategies based on massively-parallel sequencing.
shallow whole-genome sequencing, structural variation, clinical sequencing, cancer
This work was supported by Cancer Research UK [grant numbers A15973, A15601: 454 G.M, J.D.B], VUmc Cancer Center Amsterdam [VUmc-CCA: BY] and the Dutch 455 Cancer Society [VU 2015-7882: BY].
Cancer Research UK (CRUK-A15973)
Cancer Research UK (CRUK-A15601)
External DOI: https://doi.org/10.1016/j.tig.2016.07.002
This record's URL: https://www.repository.cam.ac.uk/handle/1810/257380
Attribution-NonCommercial-NoDerivatives 4.0 International, Attribution-NonCommercial-NoDerivatives 4.0 International, Attribution-NonCommercial-NoDerivatives 4.0 International
Recommended or similar items
The following licence files are associated with this item: